Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Nomegestrol→

Nomegestrol Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
58691-88-6
Molecular formula
C21H28O3
Molecular weight
328.4 g/mol
Drug class
Synthetic steroidal progestogenprogesterone-receptor agonist
Mechanism of action
Nomegestrol acetate is a selective progestogen with high affinity for progesterone receptors and anti-gonadotropic activity. In combined hormonal contraceptive products it suppresses ovulation and alters cervical mucus and the endometrium. It is marketed in the studied/authorised combination with estradiol, not as a stand-alone contraceptive in all jurisdictions.
Indications / reported uses
  • Contraception as part of the fixed-dose nomegestrol acetate/estradiol combined oral contraceptive product, where authorised.

Sources: https://www.medicines.org.uk/emc/medicine/27581 · https://www.ema.europa.eu/en/documents/product-information/ioa-epar-product-information_en.pdf · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Nomegestrol Environmental Risk Assessment (ERA) (the Nomegestrol ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.